RSRC2 and triple-negative breast carcinoma: TRA2A can reduce the level of normal RSRC2 splicing product RSRC2s and increase the expression of RSRC2l, an abnormal mRNA splicing product of RSRC2, which promotes the progression of triple negative breast cancer (Tieju Liu et al., 2017).